Milnacipran, a serotonin and norepinephrine reuptake inhibitor, induces appetite-suppressing effects without inducing hypothalamic stress responses in mice

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 292, Issue 5, 2007, Pages

  Nonogaki, Katsunori ^a   Nozue, Kana ^a   Kuboki, Tomifusa ^b   Oka, Yoshitomo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

5 hydroxytryptamine; Corticosterone; Food intake; Glucose; Norepinephrine

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; AGOUTI PROTEIN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; FENFLURAMINE; GHRELIN; GLUCOSE; MILNACIPRAN; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DECREASED APPETITE; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENERGY BALANCE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HYPERPHAGIA; HYPOTHALAMUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STRESS;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; APPETITE; APPETITE DEPRESSANTS; BLOOD GLUCOSE; CORTICOSTERONE; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; FENFLURAMINE; FOOD DEPRIVATION; HYPOTHALAMUS; MICE; SEROTONIN UPTAKE INHIBITORS; STRESS;

EID: 34248153133     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00527.2006     Document Type: Article

References (29)

1. Boyer P, Briley M. Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor. Drugs Today 34: 709-720, 1998.
2. Broberger C. Hypothalamic cocaine- and amphetamine-regulated transcript (CART) neurons: histochemical relationship to thyrotropin-releasing hormone, melanin concentrating hormone, orexin/hypocretin and neuropeptide Y. Brain Res 848: 101-113, 1999.
3. Chaouloff F, Gunn SH, Young JB. Central 5-hydroxytryptamine2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist D-fenfluramine in the conscious rat. J Pharmacol Exp Ther 260: 1008-1016, 1992.
4. Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Brain Res Rev 18: 1-32, 1993.
5. Ebihara K, Ogawa Y, Katsuura G, Numata Y, Masuzaki H, Satoh N, Tamaki M, Yoshioka T, Hayase M, Matsuoka N, Aizawa-Abe M, Yoshimasa Y, Nakao K. Involvement of agouti-related protein. An endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes 48: 2028-2033, 1999.
6. El-Giamal N, de Zwaan M, Bailer U, Strnad A, Schussler P, Kasper S. Milnacipran in the treatment of bulimia nervosa: a report of 16 cases. Eur Neuropsychopharmacol 13: 73-79, 2003.
7. Elias CF, Lee CE, Kelly JF, Ahima RS, Kuhar M, Saper CB, Elmquist JK. Characterization of CART neurons in the rat and human hypothalamus. J Comp Neurol 432: 1-19, 2001.
8. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385: 165-168, 1997.
9. Fone KC, Topham IA. Alteration in 5-hydroxytryptamine agonist-induced behaviour following a corticosterone implant in adult rats. Pharmacol Biochem Behav 71: 815-823, 2002.
10. Friedman JM. Modern science versus the stigma of obesity. Nat Med 10: 563-569, 2004.
11. Gehlert DR, Dreshfield L, Tinsley F, Benvenga MJ, Gleason S, Fuller RW, Wong DT, Hemrick-Luecke SK. The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding. J Pharmacol Exp Ther 287: 122-127, 1998.
12. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE, Cone RD, Elmquist JK. Activation of central melanocortin pathways by fenfluramine. Science 297: 609-611, 2002.
13. Kennet GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP. SB242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36: 609-620, 1997.
14. Laflamme N, Bovetto S, Richard D, Rivest S. Effect of dexfenfluramine on the transcriptional activation of CRF and its type 1 receptor within the paraventricular nucleus of the rat hypothalamus. Br J Pharmacol 117: 1021-1034, 1996.
15. Lee MD, Somerville EM, Kennett GA, Dourish CT, Clifton PG. Tonic regulation of satiety by 5-HT receptors in the mouse: converging evidence from behavioural and c-fos immunoreactivity studies? Eur J Neurosci 19: 3017-3025, 2004.
16. Lee MD, Somerville EM, Kennett GA, Dourish CT, Clifton PG. Reduced hypophagic effects of D-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice. Psychopharmacology (Berl) 176: 39-49, 2004.
17. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 371: 799-802, 1994.
18. Mochizuki D, Tsujita R, Yamada S, Kawasaki K, Otsuka Y, Hashimoto S, Hattori T, Kitamura Y, Miki N. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl) 162: 323-332, 2002.
19. Nonogaki K, Iguchi A. Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 60: 797-807, 1997.
20. Nonogaki K, Iguchi A. Stress, acute hyperglycemia, and hyperlipidemia: role of the autonomic nervous system and cytokines. Trends Endocrinol Metab 8: 192-197, 1997.
21. Nonogaki K, Ohashi-Nozue K, Oka Y. A negative feedback system between brain serotonin systems and plasma active ghrelin levels in mice. Biochem Biophys Res Commun 341: 703-707, 2006.
22. Nonogaki K, Nozue K, Takahashi Y, Yamashita N, Hiraoka S, Kumano H, Kuboki T, Oka Y. Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors. Int J Neuropsychopharmacol In press.
23. y mice. Endocrinology 147: 5893-5900, 2007.
24. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99-108, 1997.
25. Redmond AM, Kelly JP, Leonard BE. The determination of the optimal dose of milnacipran in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 62: 619-623, 1999.
26. Sugimoto Y, Yamada J, Yoshikawa T, Horisaka K. Effects of the 5-HT2C/2B receptor agonist 1-(3-chlorophenyl) piperazine on plasma glucose levels of rats. Eur J Pharmacol 307: 75-80, 1996.
27. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374: 542-546, 1995.
28. Vickers SP, Clifton PG, Dourish CT, Tecott LH. Reduced satiating effect of D-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 143: 309-314, 1999.
29. Vickers SP, Dourish CT, Kennett GA. Evidence that hypophagia induced by D-fenfluramine and D-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41: 200-209, 2001.